HDCN-- Iron Management 2000: Is There Anything New? -- Satellite Symposium, American Society of Nephrology Annual Scientific Meeting, Toronto, Ontario, Canada, October, 2000.

	Online Slide/Audio Symposium






Self Study Program based on a Satellite Symposium of the American Society of Nephrology 33rd Annual Scientific Meeting, October, 2000 This program is sponsored by Medical Education Resources, Littleton, CO. This is an approved ASN satellite symposium. It is not part of the official 33rd Annual Meeting as planned by the ASN Program Committee. Supported by an unrestricted educational grant from Watson Pharmaceuticals, Inc. Iron Management 2000: Is There Anything New?

You need to REGISTER WITH HDCN (it's free) before you can access these talks. This program offers 1.5 hours of Category One CME Credit for Physicians and 1.75 contact hours for nurses through Medical Education Resources.
For CME-related information click here


The Talks

Introductory Remarks
Steven Fishbane, MD

Iron Therapy as an Ongoing Issue in 2000
(K-DOQI Anemia Guidelines: Revisions and Performance)
Jay Wish, MD

Phase IV Sodium Ferric Gluconate Studies: Serum Iron Distribution
Paul Seligman, MD

Phase IV Sodium Ferric Gluconate Studies: Safety
Joseph Eschbach, MD

Optimal Iron Management - Optimal Iron Therapies
Allen Nissenson, MD

Questions and Answers
Drs. Fishbane, Wish, Eschbach, Seligman and Nissenson

Faculty

Joseph Eschbach, MD, Clinical Professor of Medicine, University of Washington, Seattle, WA

Steven Fishbane, MD, Associate Professor of Medicine and Associate Chairman, Department of Medicine, Winthrop-University Hospital, Mineola, NY

Allen Nissenson, MD, Professor of Medicine, Chief of Dialysis, University of California at Los Angeles, Los Angeles, CA

Paul Seligman, MD, Professor of Medicine, University of Colorado Health Sciences Center, Denver, CO

Jay Wish, MD, Professor of Medicine, Medical Director, Hemodialysis Service, Case Western Reserve University, Cleveland, OH


This is an approved ASN satellite symposium. It is not part of the official 33rd Annual Meeting as planned by the ASN Program Committee. Supported by an unrestricted educational grant from Watson Pharmaceuticals, Inc.